Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
International Business is expected to register double-digit growth in constant currency terms
New leadership team announced at NATHEALTH Annual General Meeting 2024
This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
Application based on results from the TROPION-Breast01 Phase III trial
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
Subscribe To Our Newsletter & Stay Updated
